Order Article Reprints

Licata G, Di Brizzi EV, Castelli F, Giuffrida G, Stroppiana E, Dattola A, Richetta AG, De Col E, Peila R, Siliquini N, et al. Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains—Should Psychosocial Life Impairment Be Considered a Comorbidity? Journal of Clinical Medicine. 2025; 14(1):223. https://doi.org/10.3390/jcm14010223

Licata, Gaetano, Eugenia Veronica Di Brizzi, Franco Castelli, Giorgia Giuffrida, Elena Stroppiana, Annunziata Dattola, Antonio Giovanni Richetta, Elena De Col, Rossana Peila, Niccolò Siliquini, and et al. 2025. "Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains—Should Psychosocial Life Impairment Be Considered a Comorbidity?" Journal of Clinical Medicine 14, no. 1: 223. https://doi.org/10.3390/jcm14010223

Licata, G., Di Brizzi, E. V., Castelli, F., Giuffrida, G., Stroppiana, E., Dattola, A., Richetta, A. G., De Col, E., Peila, R., Siliquini, N., Solaroli, C., Zanetta, R., Cerulli, E., Galdo, G., Giordano, D., Faure, E., Papaianni, V., Pertusi, G., Uzzauto, M. T., ... Zichichi, L. (2025). Tildrakizumab and Quality of Life: Deep Dive into the Impact of Psoriasis and Treatment on Different Domains—Should Psychosocial Life Impairment Be Considered a Comorbidity? Journal of Clinical Medicine, 14(1), 223. https://doi.org/10.3390/jcm14010223